Cameron MD - Generation Bio CEO and President
| GBIO Stock | USD 1.43 0.01 0.69% |
Insider
Cameron MD is CEO and President of Generation Bio Co
| Age | 54 |
| Address | 301 Binney Street, Cambridge, MA, United States, 02142 |
| Phone | 617 655 7500 |
| Web | https://generationbio.com |
Generation Bio Management Efficiency
The company has return on total asset (ROA) of (0.1929) % which means that it has lost $0.1929 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.865) %, meaning that it created substantial loss on money invested by shareholders. Generation Bio's management efficiency ratios could be used to measure how well Generation Bio manages its routine affairs as well as how well it operates its assets and liabilities. As of the 28th of November 2024, Return On Tangible Assets is likely to drop to -0.35. In addition to that, Return On Capital Employed is likely to drop to -0.43. At this time, Generation Bio's Non Currrent Assets Other are very stable compared to the past year. As of the 28th of November 2024, Asset Turnover is likely to grow to 0.01, while Total Assets are likely to drop about 302.1 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Charles Newton | Lyell Immunopharma | 53 | |
| Michael Carruthers | Edgewise Therapeutics | 66 | |
| Daniel Welch | Nuvation Bio | 63 | |
| Stacy Markel | Nuvation Bio | 59 | |
| CPA CPA | Stoke Therapeutics | 63 | |
| Bernard JD | Sana Biotechnology | 69 | |
| Stephanie Yao | Kronos Bio | N/A | |
| Kristina Zambouras | C4 Therapeutics | N/A | |
| Sharon Townson | Monte Rosa Therapeutics | 49 | |
| Nik Chetwyn | Erasca Inc | N/A | |
| Dawn Kalmar | Stoke Therapeutics | 46 | |
| Eric Rojas | Stoke Therapeutics | N/A | |
| Shane Williams | Century Therapeutics | N/A | |
| Michael Diem | Century Therapeutics | 53 | |
| Gary Hattersley | Nuvation Bio | 57 | |
| Isabel Aznarez | Stoke Therapeutics | 52 | |
| David MD | Erasca Inc | 40 | |
| Stephen Hill | Lyell Immunopharma | 54 | |
| MSc MBA | Passage Bio | 55 | |
| FACC MD | Stoke Therapeutics | 61 | |
| Kelly Schick | C4 Therapeutics | 44 | |
Management Performance
| Return On Equity | -0.86 | ||||
| Return On Asset | -0.19 |
Generation Bio Leadership Team
Elected by the shareholders, the Generation Bio's board of directors comprises two types of representatives: Generation Bio inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Generation. The board's role is to monitor Generation Bio's management team and ensure that shareholders' interests are well served. Generation Bio's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Generation Bio's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Robert Kotin, CoFounder Advisor | ||
| Sara Besten, Chief Officer | ||
| Tracy Zimmermann, Chief Officer | ||
| Phillip Samayoa, Chief Officer | ||
| Jasmin Tower, Chief Officer | ||
| MBA MD, Chief Officer | ||
| Cameron MD, CEO and President | ||
| MD MBA, Chief Officer | ||
| Esq JD, Chief Officer | ||
| Yalonda JD, Chief Secretary | ||
| Mark Angelino, CoFounder | ||
| Matthew Stanton, Chief Officer | ||
| MS MBA, Chief Officer |
Generation Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Generation Bio a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.86 | ||||
| Return On Asset | -0.19 | ||||
| Operating Margin | (2.21) % | ||||
| Current Valuation | 5.19 M | ||||
| Shares Outstanding | 66.79 M | ||||
| Shares Owned By Insiders | 14.51 % | ||||
| Shares Owned By Institutions | 83.88 % | ||||
| Number Of Shares Shorted | 1.48 M | ||||
| Price To Book | 0.92 X | ||||
| Price To Sales | 5.14 X |
Pair Trading with Generation Bio
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Generation Bio position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Generation Bio will appreciate offsetting losses from the drop in the long position's value.Moving together with Generation Stock
| 0.74 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
| 0.78 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
Moving against Generation Stock
| 0.8 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
| 0.68 | NAMS | NewAmsterdam Pharma | PairCorr |
| 0.36 | ESLAW | Estrella Immunopharma | PairCorr |
| 0.35 | MNOV | MediciNova | PairCorr |
| 0.33 | PHVS | Pharvaris BV | PairCorr |
The ability to find closely correlated positions to Generation Bio could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Generation Bio when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Generation Bio - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Generation Bio Co to buy it.
The correlation of Generation Bio is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Generation Bio moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Generation Bio moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Generation Bio can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Generation Bio Co. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Generation Bio. If investors know Generation will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Generation Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.17) | Revenue Per Share 0.28 | Quarterly Revenue Growth 2.52 | Return On Assets (0.19) | Return On Equity (0.86) |
The market value of Generation Bio is measured differently than its book value, which is the value of Generation that is recorded on the company's balance sheet. Investors also form their own opinion of Generation Bio's value that differs from its market value or its book value, called intrinsic value, which is Generation Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Generation Bio's market value can be influenced by many factors that don't directly affect Generation Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Generation Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Generation Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Generation Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.